Scinai Research Development from 2010 to 2025
| SCNI Stock | USD 0.76 0 0.38% |
Research Development | First Reported 2002-03-31 | Previous Quarter 618.5 K | Current Value 564.6 K | Quarterly Volatility 1.9 M |
Check Scinai Immunotherapeuti financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Scinai Immunotherapeuti's main balance sheet or income statement drivers, such as Interest Expense of 1 M, Selling General Administrative of 4.2 M or Total Revenue of 1.1 M, as well as many indicators such as Price To Sales Ratio of 3.29, Dividend Yield of 0.0 or PTB Ratio of 0.26. Scinai financial statements analysis is a perfect complement when working with Scinai Immunotherapeuti Valuation or Volatility modules.
Scinai | Research Development | Build AI portfolio with Scinai Stock |
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Check out the analysis of Scinai Immunotherapeuti Correlation against competitors. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Semiconductors & Semiconductor Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scinai Immunotherapeuti. If investors know Scinai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scinai Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.872 | Earnings Share 4 | Quarterly Revenue Growth 0.361 | Return On Assets | Return On Equity |
The market value of Scinai Immunotherapeutics is measured differently than its book value, which is the value of Scinai that is recorded on the company's balance sheet. Investors also form their own opinion of Scinai Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Scinai Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scinai Immunotherapeuti's market value can be influenced by many factors that don't directly affect Scinai Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scinai Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine if Scinai Immunotherapeuti is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scinai Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.